SRRA
Income statement / Annual
Last year (2021), Sierra Oncology, Inc.'s total revenue was $0.00,
a decrease of 100.00% from the previous year.
In 2021, Sierra Oncology, Inc.'s net income was -$94.66 M.
See Sierra Oncology, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
FY-2013
|
| Period Ended |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
12/31/2013 |
| Operating Revenue |
$0.00 |
$300,000.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$0.00
|
$300,000.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$67.15 M
|
$45.12 M
|
$53.25 M
|
$41.08 M
|
$30.16 M
|
$33.90 M
|
$26.36 M
|
$19.08 M
|
$2.84 M
|
| General & Administrative Expenses |
$27.44 M
|
$20.12 M
|
$13.74 M
|
$14.34 M
|
$12.46 M
|
$14.18 M
|
$9.47 M
|
$3.50 M
|
$1.16 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$27.44 M
|
$20.12 M
|
$13.74 M
|
$14.34 M
|
$12.46 M
|
$14.18 M
|
$9.47 M
|
$3.50 M
|
$1.16 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$94.59 M
|
$65.24 M
|
$66.99 M
|
$55.42 M
|
$42.62 M
|
$48.08 M
|
$35.83 M
|
$22.58 M
|
$4.01 M
|
| Cost And Expenses |
$94.59 M
|
$65.24 M
|
$66.99 M
|
$55.42 M
|
$42.62 M
|
$48.08 M
|
$35.83 M
|
$22.58 M
|
$4.01 M
|
| Interest Income |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$2.72 M
|
| Depreciation & Amortization |
$305,000.00
|
$238,000.00
|
$83,000.00
|
$111,000.00
|
$258,000.00
|
$197,000.00
|
$111,000.00
|
$12,000.00
|
$1,000.00
|
| EBITDA |
-$94.36 M |
-$80.52 M |
-$88.35 M |
-$53.53 M |
-$41.60 M |
-$47.53 M |
-$53.09 M |
-$23.86 M |
-$4.11 M |
| EBITDA Ratio |
0
|
-268.41
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
-216.47
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$0.00
|
-$15.82 M
|
-$21.44 M
|
$1.78 M
|
$760,000.00
|
$351,000.00
|
-$17.38 M
|
-$1.29 M
|
-$2.83 M
|
| Income Before Tax |
-$94.66 M
|
-$80.76 M
|
-$88.44 M
|
-$53.64 M
|
-$41.86 M
|
-$47.72 M
|
-$53.21 M
|
-$23.87 M
|
-$6.83 M
|
| Income Before Tax Ratio |
0
|
-269.2
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
-$3,000.00
|
$142,000.00
|
-$160,000.00
|
-$302,000.00
|
$156,000.00
|
$143,000.00
|
$55,000.00
|
$2,000.00
|
-$108,000.00
|
| Net Income |
-$94.66 M
|
-$80.90 M
|
-$88.28 M
|
-$53.34 M
|
-$42.02 M
|
-$47.87 M
|
-$53.26 M
|
-$23.87 M
|
-$6.83 M
|
| Net Income Ratio |
0
|
-269.67
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-7.14 |
-7.7 |
-30.3 |
-30.16 |
-33.68 |
-63.32 |
-147.95 |
-56.76 |
-13.19 |
| EPS Diluted |
-7.14 |
-7.7 |
-30.3 |
-30.16 |
-33.68 |
-63.32 |
-147.95 |
-56.76 |
-13.19 |
| Weighted Average Shares Out |
$13.25 M
|
$10.51 M
|
$2.91 M
|
$1.77 M
|
$1.25 M
|
$756,006.00
|
$359,987.00
|
$420,572.00
|
$518,099.00
|
| Weighted Average Shares Out Diluted |
$13.25 M
|
$10.51 M
|
$2.91 M
|
$1.77 M
|
$1.25 M
|
$756,006.00
|
$359,987.00
|
$420,572.00
|
$518,099.00
|
| Link |
|
|
|
|
|
|
|
|
|
